The DOI matches its Crossref record; 57 of the 60 references it cites were found in a registry or an index.
Androgen Receptor Gene CAG Repeat Length and Body Mass Index Modulate the Safety of Long-Term Intramuscular Testosterone Undecanoate Therapy in Hypogonadal Men
Abstract
CONTEXT: A reliable form of androgen substitution therapy regarding kinetics, tolerance, and restoration of androgenicity is paramount in hypogonadal men. Intramuscular injection of the long-acting ester testosterone undecanoate (TU) offers a new modality. OBJECTIVE: The objective of the study was to assess the safety of TU regarding metabolic and pharmacogenetic confounders. DESIGN: This was a longitudinal one-arm open observation trial. A minimum of five individual assessments was a prerequisite. Putative modulators of safety parameters entering regression models were nadir and/or delta total testosterone concentrations, body mass index, androgen receptor (AR) gene CAG repeat length, and age. SETTING: The study was conducted at an andrological outpatient clinic. PATIENTS: Patients included 66 hypogonadal men (mean age 38 +/- 9.9 yr). MAIN OUTCOME MEASURES: A total of 515 data time points each related to prostate, erythropoiesis, lipoproteins, and circulation during 118 treatment-years with 1000 mg TU at 10- to 14-wk intervals. RESULTS: Testosterone substitution resulted in significant decrements of serum levels of low-density lipoprotein-cholesterol, resting diastolic and systolic blood pressure, and heart rate. Erythropoiesis was stimulated and concentrations of high-density lipoproteincholesterol increased. Parameters remained stable after four injections. No adverse effects regarding the prostate were observed. Significantly increased hematocrit greater than 50% was predicted by enhanced androgen action (shorter AR CAG repeats per higher testosterone levels). However, insufficient androgen action (longer AR CAG repeats per lower testosterone levels) caused pathological safety parameters (high blood pressure, adverse lipid profiles). In addition, a body mass index 30 kg/m(2) or greater represents a clinically relevant factor for the occurrence of all pathological safety parameters. Risk calculations for obese patients and nonlinear pharmacogenetic models to tailor androgen substitution are presented. CONCLUSIONS: Testosterone substitution with im TU is generally well tolerated. Modifications of androgen action are due to both AR CAG repeats and testosterone levels. Adverse observations are mostly seen in obese patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prostate-specific antigen and volume rise, marginally, plateauing at 12 months; further increase should be related to aging rather than therapy.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [44]
In the citing paper
“The decrease in low-density lipoprotein cholesterol seems somewhat slower: after 3 months (35), after 40–44 weeks, (44) or after 12 months (42) with a maximum observed after 24 months (32).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [44]
In the citing paper
“An increase was found to occur after 3 months increasing further during 12 months (43), after 6 months, (35) or close to 1 year (44). Continuous increase was observed over 24 months (32).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [44]
In the citing paper
“A decrease in the resting heart rate occurred after 40–44 weeks (44).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [44]
In the citing paper
“The effects of testosterone on red blood cell formation (hemoglobin and hematocrit) are dose dependent (14, 82, 83) while higher age is also a factor (44).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [44]
In the citing paper
“An increase in prostate volume was noted after 3 months (86) and after 12 months (44).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [44]
Citations
Cites
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Testosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Calof, O. M., Singh, A. B., Lee, M. L., Kenny, A. M., Urban, R. J., Tenover, J. L., & Bhasin, S. (2005) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/60.11.1451 · Cited by 728
Isidori, A. M., Giannetta, E., Greco, E. A., Gianfrilli, D., Bonifacio, V., Isidori, A., Lenzi, A., & Fabbri, A. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02339.x · Cited by 695
Wang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A. M., Snyder, P. J., Weber, T., Berman, N., Hull, L., & Swerdloff, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032006 · Cited by 656
Association of Specific Symptoms and Metabolic Risks with Serum Testosterone in Older Men
Zitzmann, M., Faber, S., & Nieschlag, E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0401 · Cited by 552
Self-citationBhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Mac, R. P., Lee, M., Yarasheski, K. E., Sinha-Hikim, I., Dzekov, C., Dzekov, J., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1184 · Cited by 544
Effect of Testosterone Treatment on Body Composition and Muscle Strength in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.8.2647 · Cited by 531
Flagged first, then by citations
3 of the 60 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 216
Stanworth, R. D., Akhtar, S., Channer, K. S., & Jones, T. H. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0703 · Cited by 25
Ruamyod, K., Watanapa, W. B., & Shayakul, C. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.02.014 · Cited by 24
12-Month Observation of Testosterone Replacement Effectiveness in a General Population of Men
Miner, M. M., Bhattacharya, R. K., Blick, G., Kushner, H., & Khera, M. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.03.2637 · Cited by 25
Microarray Analysis of the Major Depressive Disorder mRNA Profile Data
Gao, L., Gao, Y., Xu, E., & Xie, J. M. (2015) · Psychiatry Investigation · doi:10.4306/pi.2015.12.3.388 · Cited by 23
The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts
Kırlangıç, O. F., Yilmaz‐Oral, D., Kaya‐Sezginer, E., Toktanis, G., Tezgelen, A. S., Sen, E., Khanam, A., Öztekin, Ç. V., & Gür, S. (2020) · Sexual Medicine · doi:10.1016/j.esxm.2020.02.006 · Cited by 23
Testosterone and Coronary Artery Disease
Schwarcz, M., & Frishman, W. H. (2010) · Cardiology in Review · doi:10.1097/crd.0b013e3181e84673 · Cited by 21
Testosterone Replacement Therapy and Components of the Metabolic Syndrome
Anaissie, J. E., Roberts, N. H., Wang, P., & Yafi, F. A. (2017) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2017.01.003 · Cited by 21
New approaches to the Klinefelter syndrome
Nieschlag, E., Werler, S., Wistuba, J., & Zitzmann, M. (2014) · Annales d Endocrinologie · doi:10.1016/j.ando.2014.03.007 · Cited by 20
Self-citationElevated Dihydrotestosterone is Associated with Testosterone Induced Erythrocytosis
Aghazadeh, M. A., Pastuszak, A. W., Johnson, W. G., McIntyre, M. G., Hsieh, T., & Lipshultz, L. I. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.01.038 · Cited by 19
Zitzmann, M., Cremers, J. F., Krallmann, C., & Kliesch, S. (2022) · The Aging Male · doi:10.1080/13685538.2022.2063830 · Cited by 20
Self-citationSchulze, J. J., Rane, A., & Ekström, L. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902976862 · Cited by 19
Dogan, B. A., Karakılıç, E., Tuna, M. M., Arduç, A., Berker, D. S., & Güler, S. (2014) · Clinical Endocrinology · doi:10.1111/cen.12617 · Cited by 18
Chasland, L. C., GREEN, D. J., Schlaich, M. P., Maiorana, A., Cooke, B. R., Cox, K. L., Naylor, L. H., & Yeap, B. B. (2021) · Clinical Endocrinology · doi:10.1111/cen.14442 · Cited by 19
Tessnow, A. H., Olsen, N. J., & Kovacs, W. J. (2011) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9519-5 · Cited by 18
A Hormonal Contraceptive for Men: How Close are We?
Huhtaniemi, I. T. (2010) · Progress in brain research · doi:10.1016/s0079-6123(08)81015-1 · Cited by 17
Kumagai, H., Miyaki, A., Higashino, R., Akazawa, N., Choi, Y., Ra, S., Eto, M., Tanaka, K., Ajisaka, R., & Maeda, S. (2014) · Artery Research · doi:10.1016/j.artres.2014.04.003 · Cited by 15
Kornmann, B., Nieschlag, E., Zitzmann, M., Gromoll, J., Simoni, M., & von Eckardstein, S. (2009) · Journal of Andrology · doi:10.2164/jandrol.108.006296 · Cited by 16
Self-citationMale Hormonal Contraception: Love’s Labour’s Lost?
Nieschlag, E. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0704 · Cited by 16
Self-citationSchneider, G., Zitzmann, M., Gromoll, J., Ladwig, K., & Berger, K. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.03.016 · Cited by 15
Self-citationConaglen, H. M., Paul, R. G., Yarndley, T., Kamp, J., Elston, M. S., & Conaglen, J. V. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12401 · Cited by 15
Nieschlag, E., & Behre, H. M. (2009) · Springer eBooks · doi:10.1007/978-3-540-92963-5_21 · Cited by 14
Self-citationAndrogen modulates cardiac fibrosis contributing to gender differences on heart failure
Chung, C., Kao, Y., Chen, Y., & Chen, Y.-J. (2013) · The Aging Male · doi:10.3109/13685538.2012.754008 · Cited by 13
Haider, A., Gooren, L. J., Padungtod, P., & Saad, F. (2010) · Andrologia · doi:10.1111/j.1439-0272.2009.01016.x · Cited by 13
Abildgaard, J., Petersen, J. H., Bang, A. K., Aksglæde, L., Christiansen, P., Juul, A., & Jørgensen, N. (2021) · Andrology · doi:10.1111/andr.13124 · Cited by 13
Testosterone Replacement Therapy: Effects on Blood Pressure in Hypogonadal Men
Hackett, G. I., Mann, A., Haider, A., Haider, K. S., Desnerck, P., König, C. S., Strange, R. C., & Ramachandran, S. (2024) · The World Journal of Men s Health · doi:10.5534/wjmh.230239 · Cited by 12
Abdel‐Hamid, I. A., & Andersson, K. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.104 · Cited by 12
Lipid Effects of Endocrine Medications
Mihailescu, D. V., Vora, A., & Mazzone, T. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0146-z · Cited by 12
Hayden, R. P., Bennett, N., & Tanrikut, C. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.05.110 · Cited by 11
Eendebak, R. J. A. H., Huhtaniemi, I. T., Pye, S. R., Ahern, T., O’Neill, T. W., Bártfai, G., Casanueva, F. F., Maggi, M., Forti, G., Alston, R. D., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0447 · Cited by 10
Majzoub, A. A., & Shoskes, D. A. (2016) · Translational Andrology and Urology · doi:10.21037/tau.2016.07.09 · Cited by 10
Hypothalamic–Pituitary–Gonadal Axis in Men
Swerdloff, R. S., Wang, C., & Hikim, A. P. S. (2009) · Elsevier eBooks · doi:10.1016/b978-008088783-8.00075-9 · Cited by 10
Die Therapie des Hypogonadismus des Mannes
Zitzmann, M. (2008) · Der Internist · doi:10.1007/s00108-008-2108-x · Cited by 9
Self-citationSağlam, H. S., Cakar, M., Köse, O., Kumsar, Ş., Budak, S., Beyaz, S. G., & Adsan, Ö. (2012) · Open Journal of Urology · doi:10.4236/oju.2012.223029 · Cited by 8
Late-onset hypogonadism or ADAM: diagnosis
Martits, A., Costa, E., Nardi, A., Nardozza, A., Faria, G., Facio, F., & Bernardo, W. (2014) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.60.04.003 · Cited by 8
The History of Testosterone and The Testes: From Antiquity to Modern Times
Nieschlag, E., & Nieschlag, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-46086-4_1 · Cited by 8
Self-citationWang, H. Y., Hu, Y., Wang, S. H., Shan, Q. L., Li, Y. C., Nie, J., Long, Y., Bao, D., Xu, C., & He, Z.-H. (2010) · International Journal of Andrology · doi:10.1111/j.1365-2605.2009.01027.x · Cited by 8
Olsen, N. J., Benko, A. L., & Kovacs, W. J. (2014) · Endocrine Connections · doi:10.1530/ec-14-0039 · Cited by 9
Testosterone in men's health: a new role for an old hormone
Feeley, R. J., Saad, F., Guay, A. T., & Traish, A. M. (2009) · Journal of Men s Health · doi:10.1016/j.jomh.2009.06.005 · Cited by 8
Malavige, L. S., Jayawickrama, S., Ranasinghe, P. D., & Lévy, J. (2017) · BMC Research Notes · doi:10.1186/s13104-017-3035-5 · Cited by 7
Pharmacogenomics of Osteoporosis
Gennari, L. (2010) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-010-9071-5 · Cited by 6
The number of androgen receptor CAG repeats and mortality in men
Heald, A. H., Cook, M. J., Antonio, L., Vanderschueren, D., Javed, A. Y., Fachim, H., Hackett, G. I., Wu, F. C. W., & O’Neill, T. W. (2022) · The Aging Male · doi:10.1080/13685538.2022.2061452 · Cited by 5
New Horizons: Testosterone or Exercise for Cardiometabolic Health in Older Men
GREEN, D. J., Chasland, L. C., Naylor, L. H., & Yeap, B. B. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad175 · Cited by 5
Deficiência de Testosterona em Homens Hipertensos: Prevalência e Fatores Associados
Negretto, L. A. F., Rassi, N., Soares, L. R., Saraiva, A. B. C., Teixeira, M. E. F., Santos, L. D. R., Souza, A. L. L., Jardim, P. C. B. V., Barroso, W. K. S., & Jardim, T. V. (2024) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20230138 · Cited by 7
Butler, M. G., & Manzardo, A. M. (2015) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-015-0484-4 · Cited by 5
Testosterone and cardiovascular disease
Channer, K. S., & Jones, T. H. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003353.011 · Cited by 5
Sequelae of doping with anabolic steroids
Vorona, E., & Nieschlag, E. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003353.026 · Cited by 6
Self-citationMann, A., Strange, R. C., Hackett, G. I., König, C. S., & Ramachandran, S. (2024) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2024.00010 · Cited by 4
Role of Androgens in Cardiovascular Diseases in Men: A Comprehensive Review
Mukherjee, D., Sen, K., Gupta, S., Chowdhury, P. D., Majumder, S., & Guha, P. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.85852 · Cited by 5
Number of CAG repeats and mortality in middle aged and older men
Heald, A. H., Cook, M. J., Antonio, L., Tournoy, J., Ghaffari, P., Mannan, F., Fachim, H., Vanderschueren, D., Laing, I., Hackett, G. I., et al. (2023) · Clinical Endocrinology · doi:10.1111/cen.14962 · Cited by 4
Lethin, K., Aardal, E., Lood, Y., Ekman, B., & Wahlberg, J. (2023) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfad096 · Cited by 5
Nieschlag, E., & Behre, H. M. (2010) · Springer eBooks · doi:10.1007/978-3-540-78355-8_21 · Cited by 4
Self-citationBehre, H. M. (2008) · Elsevier eBooks · doi:10.1016/b978-012373960-5.00474-3 · Cited by 4
Behre, H. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803678-5.00265-4 · Cited by 4
Dhiman, P., Bhansali, A., Prasad, R., Dutta, P., Walia, R., & Ravikiran, M. (2011) · Andrologia · doi:10.1111/j.1439-0272.2010.01093.x · Cited by 3
Management of hematocrit levels for testosterone replacement patients, a narrative review
Fink, J. E., Bentzen, K., & Horie, S. (2025) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeaf013 · Cited by 3
Senescence and Late-Onset Hypogonadism
Rolf, C., Zitzmann, M., & Nieschlag, E. (2023) · Springer eBooks · doi:10.1007/978-3-031-31574-9_25 · Cited by 3
Self-citationRamachandran, P., Zitzmann, M., König, C. S., Mulhern, J., Ramachandran, S., & Hackett, G. I. (2024) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2024.00015 · Cited by 3
Self-citationKim, M. J., Kim, J. T., Cho, S. W., Kim, S. W., Shin, C. S., Park, K. S., & Kim, S. Y. (2011) · Endocrinology and Metabolism · doi:10.3803/enm.2011.26.3.225 · Cited by 3
Králik, M., Cvečka, J., Buzgó, G., Putala, M., Ukropcová, B., Ukropec, J., Killinger, Z., Payer, J., Kollárik, B., Bujdák, P., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025991 · Cited by 3
Nieschlag, E., & Behre, H. M. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-61901-8_36 · Cited by 2
Self-citationAndrogens: Pharmacological Use and Abuse ☆
Byrne, M. M., & Nieschlag, E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.03356-3 · Cited by 2
Self-citationTestosterone Deficiency in Hypertensive Men: Prevalence and Associated Factors
Negretto, L. A. F., Rassi, N., Soares, L. R., Saraiva, A. B. C., Teixeira, M. E. F., Santos, L. D. R., Souza, A. L. L., Jardim, P. C. B. V., Barroso, W. K. S., & Jardim, T. V. (2024) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20230138i · Cited by 2
Haider, K. S., Zitzmann, M., Ramachandran, P., König, C. S., Hackett, G. I., Haider, A., Saad, F., Desnerck, P., Strange, R. C., Mann, A., et al. (2024) · The Aging Male · doi:10.1080/13685538.2024.2357548 · Cited by 2
Self-citationLate-onset hypogonadism or ADAM: treatment
Martits, A., Costa, E., Nardi, A., Nardozza, A., Facio, F., Faria, G., & Bernardo, W. (2014) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.60.05.005 · Cited by 2
Hormones and visual attention to sexual stimuli in older men: an exploratory investigation
Palmer‐Hague, J. L., Wong, S. T. S., Wassersug, R. J., Kingstone, A. F., & Wibowo, E. (2021) · The Aging Male · doi:10.1080/13685538.2021.1960964 · Cited by 2
The Aging Male and Late-Onset Hypogonadism
Rolf, C., Zitzmann, M., & Nieschlag, E. (2010) · Springer eBooks · doi:10.1007/978-3-540-78355-8_14 · Cited by 2
Self-citationTestosterone replacement and cardiovascular disease risk
Gonzalez, J. R., & Goldstein, I. (2015) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000051 · Cited by 2
Morgentaler, A., Zitzmann, M., Traish, A. M., Fox, A. W., Jones, T. H., Maggi, M., Arver, S., Aversa, A., Chan, J. C. N., Dobs, A. S., et al. (2016) · Obesity and metabolism · doi:10.14341/omet2016315-31 · Cited by 2
Self-citationQuantitative Influence of Exogenous Androgens on Serum Lipid Profile and Endocrine Functions
Gårevik, N. (2013) · Figshare · Cited by 2
Seneszenz und Altershypogonadismus
Rolf, C., Zitzmann, M., & Nieschlag, E. (2009) · Springer eBooks · doi:10.1007/978-3-540-92963-5_14 · Cited by 1
Self-citationCan the administration of testosterone to men with late-onset hypogonadism be discontinued?
Gooren, L. J. (2008) · Journal of Men s Health · doi:10.1016/j.jomh.2008.09.005 · Cited by 1
Congenital Hypogonadotropic Hypogonadism and Kallmann's Syndrome☆
Rohayem, J., Zitzmann, M., & Nieschlag, E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.98874-3 · Cited by 1
Self-citationNieschlag, E., & Behre, H. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-31574-9_36 · Cited by 1
Self-citationWang, C., Nieschlag, E., Swerdloff, R. S., Behre, H. M., Hellstrom, W. J. G., Gooren, L. J., Morales, Á., Kaufmann, J. M., Legros, J.-J., Lunenfeld, B., et al. (2010) · Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) · Cited by 1
Self-citationKazakov, R. E., Rozhivanov, R. V., & Ших, Е. В. (2019) · Andrology and Genital Surgery · doi:10.17650/2070-9781-2019-20-1-13-21 · Cited by 1
Testosteronmangel im Alter: Normal oder pathologisch?
Kliesch, S. (2015) · Deutsches Ärzteblatt · doi:10.3238/persuro.2015.0911.04 · Cited by 1
Gheorghiu, M. L. (2008) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2008.59 · Cited by 1
Filho, A. B. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2018.tde-15082018-090700 · Cited by 2
ERKRANKUNGEN DER ENDOKRINEN ORGANE UND DES STOFFWECHSELS
Jung, N., Mayet, W.-J., Mertens, P. R., Meyer, J. S., Müller, O.-A., Pfeifer, M., Schellinger, P. D., Weiss, N., & Wendtner, C.-M. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-06282-7.50015-2 · Cited by 1
Hypogonadism: Biochemical Diagnosis, Treatment, and the Myth of Uniform Thresholds
Zitzmann, M. (2013) · Journal of Men s Health · doi:10.1089/jomh.2009.00030
Self-citationAktuelle Aspekte: Altershypogonadismus und das metabolische Syndrom des Mannes
Zitzmann, M. (2008) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Self-citationKristianingrum, Y. P. (2014)
Wang, C., Nieschlag, E., Swerdloff, R. S., & Wu, F. C. W. (2008) · European Urology · doi:10.1016/j.eururo.2008.11.054
Self-citationWang, C., Nieschlag, E., RONALD, S. S., Behre, H. M., WAYNE, J. H., LOUIS, J. G., JEAN, M. K., Legros, J., Lunenfeld, B., Morales, Á., et al. (2010) · Obesity and metabolism · doi:10.14341/2071-8713-5211
Self-citationReview Testosterone and Erectile Dysfunction
Yassin, A. A., Saad, F., & Schering, B. (2008)
Dhiman, P., Bhansali, A., Prasad, R., Dutta, P. C., Walia, R., & Ravikiran, M. (2011)
Short title - Testosterone and Erectile Dysfunction
Yassin, A. A., Saad, F., & Schering, B. (2008)
Testosterone replacement therapy
Vrolyk, M. (2015) · OpenBU (Boston University)
Testosterone and Risk Factors in the Metabolic Syndrome: Implications for Erectile Dysfunction
Guay, A. T., & Traish, A. M. (2011)
Central Hypogonadism in the Male: Physiopathology, Diagnosis and Treatment
Rohayem, J., & Nieschlag, E. (2017) · Endocrinology · doi:10.1007/978-3-319-38681-2_10-1
Self-citationCongenital and Acquired Polycythemias: Testosterone Induced Polycythemias
Nieschlag, E. (2008) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2008.0480c
Self-citationEffects of testosterone levels on mortality and cardiovascular risk in men with Type 2 diabetes
Muraleedharan, V. (2018) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
(2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32830c6b8e
Current awareness: Pharmacoepidemiology and drug safety
(2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1486
Lopès, P., & Poudat, F.-X. (2021) · Elsevier eBooks · doi:10.1016/b978-2-294-77438-6.00005-x
Central Hypogonadism in the Male: Physiopathology, Diagnosis, and Treatment
Rohayem, J., & Nieschlag, E. (2018) · Endocrinology · doi:10.1007/978-3-319-44444-4_10
Self-citationTreatment of hypogonadism and infertility
Nieschlag, E. (2011) · doi:10.1093/med/9780199235292.003.9104
Self-citation
Metadata
- Authors
- Zitzmann, M., & Nieschlag, E.
- Affiliations
- University Hospital Münster (DE)
- Corresponding author
- Nieschlag, Eberhard
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2007-10-01
- Volume
- 92
- Issue
- 10
- Pages
- 3844-3853
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2127886125
- Cited by
- 216
- References
- 60
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 9 · 2023: 12 · 2022: 2 · 2021: 6 · 2020: 3 · 2019: 8 · 2018: 4 · 2017: 10 · 2016: 9 · 2015: 17 · 2014: 19 · 2013: 15 · 2012: 10
- FWCI
- 16.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Keywords
- testosterone undecanoate, androgen receptor gene, CAG repeat length, hypogonadism, testosterone replacement therapy, body mass index, obesity, pharmacogenetics, lipid profile, blood pressure, erythropoiesis, hematocrit, prostate
- MeSH terms
- Adult, Humans, Hypogonadism, Injections, Intramuscular, Male, Middle Aged, Obesity, Pharmacogenetics, Receptors, Androgen, Regression Analysis, Testosterone, Body Mass Index, Nonlinear Dynamics, Trinucleotide Repeats, Testosterone Congeners
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
